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patients. However, vaccine efﬁcacy is limited by effector cell dysfunc-
tion and increased presence of regulatory T cells characteristic of
cancer patients. Ligation of CD3/CD28 delivers an antigen-indepen-
dent stimulus to resting T cell populations. We postulated that stim-
ulation with DC/tumor fusions followed by anti-CD3/CD28 would
result in the signiﬁcant expansion of activated T cells targeting tumor
antigens. DCs were generated from adherent mononuclear cells cul-
tured with rhIL-4, GM-CSF and TNF and fused with RCC by
coculture in 50% solution of polyethylene glycol. T cells were stim-
ulated by DC/tumor fusions prior to or following exposure to an-
tiCD3/CD28 antibody coated plates for 48 hours. A dramatic, statis-
tically signiﬁcant, increase in T cell proliferation was observed
following the sequential exposure to DC/RCC fusions and anti-CD3/
CD28 (SI 13.2). In contrast, stimulation by anti-CD3/CD28, DC/
tumor fusions, or anti-CD3/CD28 followed by fusion cells did not
result in signiﬁcant T cell proliferation. Similarly, sequential stimula-
tion byDC/RCC fusion cells followed by anti-CD3/CD28 resulted in
a nearly 8 fold expansion of CD4/CD25 cells (n10, p0.001
compared to unstimulated T cells). A 16 fold increase in CD4/CD25/
CD69 cells was observed consistent with the expansion of activated
T cells. In contrast, exposure to anti-CD3/CD28 alone or anti-CD3/
CD28 followed by stimulation with fusion cells resulted in a 3 fold
expansion of CD4/CD25 T cells and a modest expansion of CD4/
CD25/CD69 cells. In concert with these ﬁndings, IFN production
by CD4 T cells was most pronounced following stimulation with
DC/tumor fusions and expansion with anti-CD3/CD28 (p.01). In 9
experiments, stimulation with DC/RCC fusions followed by expan-
sion with anti-CD3/CD28 also resulted in a 5-fold and 4.6 fold
expansion of CD4/CD25/Foxp3 and IL-10 expressing T cells, re-
spectively. In conclusion, we have demonstrated that stimulation of T
cells by DC/RCC fusions followed by exposure to anti-CD3/CD28
antibodies results in the expansion of tumor reactive T cells that
predominantly express markers of activation. We are developing a
clinical trial in which patients will receive fusion/CD3/CD28 ex-
panded T cells following in vivo depletion of regulatory T cells.
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 T CELLS AS IMMUNOTHERAPY FOR GLIOBLASTOMA MULTIFORME
Suarez, C.1, Bryant, N.L.1, Gillespie, Y.1, Lopez, R.D.1,
Markert, J.M.1, Lamb, L.S.1 1University of Alabama at Birmingham,
Birmingham, AL.
Background:Despite advances in therapy, the survival for glioblas-
toma multiforme (GBM) has remained unchanged for 50 years. We
have investigated a cellular therapeutic therapy based on innate im-
mune recognition of GBM using ex vivo expanded  T cells that are
highly cytotoxic to GBM lines. Unlike 	CD8 cytotoxic T lym-
phocytes,  T cells act directly against stress-associated antigens
expressed on GBM and do not require MHC antigen recognition.
Methods: We examined the circulating  T cell number and
function in healthy controls and patients at speciﬁc times; diagnosis,
1-14 days post resection, and 8-14 weeks post resection. Absolute
lymphocyte and subset counts including  T cell counts were exam-
ined using ﬂow cytometry. Functional response of  T cells was
determined by proliferation in our clinically compliant expansion
procedure and subsequent in vitro and in vivo cytotoxicity assays.
Expansion cultures were harvested after two weeks and enriched for
 T cells by immunomagnetic depletion of CD4 and CD8 T
cells. Cytotoxicity of expanded T cells was evaluated in vitro against
GBM primary tumor cultures, established GBM cell lines and cul-
tured astrocytes. In vivo assays were conducted in athymic nude mice
against new and established luciferase-transduced human U251 GBM
xenografts.
Results: At diagnosis, the circulating  T cell count is not signif-
icantly less than controls (p  0.12). The absolute CD3 and CD4
count increase immediately after resection, likely due to removal of
GBM-derived immunosuppressive cytokines. Surprisingly however,
individual patients show a decrease in  T cell counts at this time.
Expansion of  T cells from pre-resection GBM patients did not
differ from controls (p  0.32, n4). although  T cell expansion
was signiﬁcantly impaired after cytoreductive therapy (p  .007,
n5). Expanded  T cells retain cytotoxicity against U251 and 1047
GBM cell lines and GBM primary cultures but spare normal astro-
cytes. Expanded  T cells slow the growth of U251 intracranial
xenografts in athymic nude mice (p .008) vs sham-treated controls.
Preliminary observations suggest that growth of established U251
xenografts is slowed in selected animals as well.
Conclusions: GBM and therapy-induced immunosuppression
present a formidable barrier to systemic cellular therapy. However,
intracranial immunotherapy using expanded allogeneic  T cells
represents a potentially effective immunotherapeutic strategy against
GBM.
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SEMI-HIGH-DOSE AUTOLOGOUS AND A NON-MYELOABLATIVE RE-
DUCED INTENSITY CONDITIONING ALLOGENEIC TRANSPLANTS INTE-
GRATED IN STANDARD OR DOSE DENSE THERAPY FOR BREAST CAN-
CER: COST-EFFICIENCY ANALYSES SUPPORT DESIGN OF COST-
EFFICIENT THERAPIES
Van Hoef, M.E.H.M.1 1Transplant Creations, Amsterdam, NH, Neth-
erlands.
Introduction: DFS at 5 yr in LN BrCa depends on status at
diagnosis and is on average 60% and in MBrCa 15%. HD-auto-Tx
add signiﬁcant DFS advantage of 5% to 10% but statistically this is
not a signiﬁcant improvement of survival. In large series TRM of
HD-auto-Tx is on average 3% in the adjuvant and up to 10% in the
metastatic setting. Semi-HD is rarely associated with TRM. Alloge-
neic transplants (allo-Tx) induce an immune response in BrCa that
may eradicate minimal residual disease if the Tx is administered in
molecular remission. Based on these facts and existent collaborative
patterns we designed in 2000 a treatment plan consisting of dose
dense induction, two semi-HD-auto-Tx and a NMRICTx and de-
cided to perform upfront cost computation.
Methods: In the Netherlands a cost system is used consisting of so
named “diagnose behandelingscombinaties” (DBC) or diagnosis
treatment combinations. In general costs are to be collected for each
item or service independently. We used the therapeutic model de-
scribed here above to compute the costs of treatment and used as-
sumption based on literature data to deﬁne disease outcome at 5 yr for
premenopausal women with ER, her-2-neu negative BrCa. For
each therapy median DFS was used to deﬁne outcomes. Disease
outcomes were deﬁned as alive without disease, alive with disease,
death and toxic death. Utilities for treatment and outcome were
derived from literature; The approach followed our Markov model
design of 2001.
Results: Disease outcomes at 5 yr of LN  BrCa by respectively 4
cycles induction ChT (1), two semi-HD- auto-Tx (2) and a non-
myeloablative reduced intensity conditioning Tx (3) with donor were
anticipated to be 60%, 70% and 90% without and 15% with relapse.
DBCwere identiﬁed and included costs for ﬁrst, second and third line
ChT on outpatient basis, or with a hospital episode, costs of hormonal
therapy, of a visit without procedure, of auto- and allo- stem cell
mobilization and leukapheresis, of auto-and allo-Tx, of post Tx care,
of follow-up, of terminal care. We adjusted for the fact that the DBC
costs are based on HD- and ablative ChT whereas our approach uses
semi-HD andNMRIC respectively. The computations of the cost per
treatment with follow-up of ﬁve years showed that standard/dose
dense ChT followed by hormonal therapy adds up to  100,000 and
that Tx types add each  50,000 by use of adjusted rates for HD-/
ablative Tx.
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THE ROLE OF HUMAN CYP2B6 POLYMORPHISM IN THE BIOACTIVA-
TION OF CYCLOPHOSPHAMIDE USING CDNA EXPRESSED ENZYMES
Afsharian, P.1, Terelius, Y.2, Hidestrand, M.3, Ingelman-Sundberg, M.3,
Hassan, M.4,5, Lundgren, S.5 1Karolinska Institutet, Department of Med-
icine, Stockholm, Sweden; 2Medivir AB, Department of Bioscience,
Stockholm, Sweden; 3Karolinska Institutet, Department of Physiology
and Pharmacology, Stockholm, Sweden; 4Karolinska University Hospital,
Poster Session I70
Huddinge, Stockholm, Sweden; 5Karolinska Institutet, Department of
Laboratory Medicine, Stockholm, Sweden.
Cyclophosphamide (CPA) is used for the treatment of many
tumors and as a part of the conditioning regimen prior to stem cell
transplantation. CPA is a prodrug that is activated through cyto-
chrome P450 2B6 (CYP2B6) in the liver. A high degree of inter-
and intra-individual variation in CPA pharmacokinetics has been
reported. We have investigated the formation of its active metab-
olite 4-hydroxycyclophosphamide (4-OH-CPA) in vitro using
three different mutants of recombinant 2B6. The rate of formation
of 4-OH-CPA was correlated to the enzyme activity for different
mutations. Different concentrations of CPA (0-10 mM) have been
incubated with microsomes from yeast cells expressing human
CYP2B6*1 and the alleles *4, *6 as well as the point mutation
G516T. The lowest Km was observed in wild type 2B6 which also
gave the lowest Vmax (0.884 mM and 175 pmol/min/pmol P450,
respectively). The ratio of Vmax/Km was 3-4 fold higher with
CYP2B6*1 than with any of the mutants (*4, *6 and G516T).
These results did not correlate with clinical data where patients,
with hematological malignancies, having the CYP2B6 G516T mu-
tation have been shown by Xie et al to have higher rates of CPA
4-hydroxylation. In vitro, however, all three mutant alleles were
shown to have less CPA 4-hydroxylase activity than CYP2B6*1,
possibly due to the high reductase activity of the cDNA-expressed
CYP2B6*1 used as wild type for comparison.
In this paper, we propose that the discrepancy seen may depend
on the ratio between the expressed levels of NADPH-cytochrome
P450 reductase and cytochrome P450 in the cells used, especially
in those expressing CYP2B6*1. Very high reductase to P450 ratios
could enhance fast reactions, like CPA 4-hydroxylation, where the
electron transfer may be rate limiting. The ratios in the micro-
somes used are not physiologically relevant and points out one
difﬁculty in scaling from in vitro to in vivo. To evaluate the effect
of the relative amount of reductase, we also used efavirenz as a slow
substrate for CYP 2B6. Our results showed similar activity for the
mutated enzymes for efavirenz compare the clinical data in HIV-1
patients, less enzyme activity of mutants G516T and *6 involved in
efavirenz metabolism compare to wild type and also less activity
was observed for *4. We concluded that the polymorphism of the
CYP2B6 gene will inﬂuence the CPA metabolism and that it may
be important to determine the genotype of the patients before
starting treatment.
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TPO INDUCES HEMATOPOIETIC DIFFERENTIATION OF HUMAN ES
CELLS
Srivastava, A.S.1, Nedelcu, E.2, Mishra, R.3, Carrier, E.1 1University
of California Medical Center, La Jolla, CA; 2UCLA-Harbor, Los An-
geles, CA; 3Case Western University, Cleveland, OH.
Recently, it was demonstrated that TPO enhances hematopoietic
differentiation of primate ES cells, but its role in differentiating
human ES cells is unknown. Therefore, we sought to investigate
the regulatory mechanism of TPO induced signals mediated by the
c-mpl cytoplasmic domain during human embryonic stem (hES)
cells hematopoietic commitment. We hypothesize that in human
embryonic stem cells, binding of TPO to its c-mpl receptor causes
three-dimensional alterations which bring the c-mpl cytoplasmic
domain and Janus Kinase into close-proximity and thus induces the
phosphorylation and dimerization of STAT5 molecule. Dimerized
STAT5 molecules detach from the receptors and migrate to the
nucleus where they bind GAS site and induce transcription of a set
of target, hematopoiesis-related genes. NIH human ES cell lines
(WI01) were used. In brief, to achieve EB formation, cells were
incubated in differentiation medium, which consisted of knockout
DMEM medium (GIBCO/BRL, Carlsbad, USA), supplemented
with 20% non-heat-inactivated fetal bovine serum (FBS, Hyclone,
USA), 1% nonessential amino acids, 1 mM L-glutamine, and 0.1
mM 	-mercaptoethanol. Subsequently, DMEM was replaced by
IMDM (GIBCO/BRL, USA) with the same supplements and ad-
ditional two cytokines (100 ng/mL SCF and 100 ng/mL Flt-3
ligand (Flt-3L)) (control group). To investigate the role of TPO
and VEGF, cells were additionally treated with 100 ng/mL TPO
alone or in combination with 100 ng/mL rhVEGF. All cytokines
were from the R&D systems (USA). There was a signiﬁcant in-
crease in the numbers of embryoid bodies (EBs) formation in TPO
(125/105), TPO/VEGF (150/105 cells) when compared to controls
(10/105 planted ES cells). This corresponded to the increase in
CFU-C and speciﬁc progenitors (CD31/CD34 positive) and in
hematopoietic (CD34-positive cells) cells. Analysis of gene expres-
sion during hematopoietic development demonstrated that TPO/
VEGF combination increased mRNA expression of the TPO re-
ceptor (TPO-R) and VEGF (VEGF-R) receptors in hematopoietic
progenitors as well as CD34 cells. We are in the process of
determining the role of JAK/STAT pathway .in this process. Func-
tional studies will involve blocking of TPO/c-mpl using TPO-R-
speciﬁc antibodies and determining its impact on human ES-
derived hematopoiesis.
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INTESTINAL TISSUE ENGINEERING: A PRELIMINARY STUDY OF LONG
TERM IN VITRO PRIMARY CULTURE OF INTESTINAL EPITHELIAL CELLS
Gandia, C.1, David, A.1, Santiago, S.1, Ruiz, P.2, Tzakis, A.1,
Kleiner, G.1 1Department of Surgery, University of Miami, Miami, FL;
2Department of Pathology, University of Miami, Miami, FL.
Clinical conditions of the small bowel such as congenital or
surgical resection may affect the functional capability of the mu-
cosal lining of the intestinal tract. Despite recent advances in small
bowel transplantation, organ shortages remain an issue. Models
that mimic the intestinal niche provide opportunities to evaluate
stem cell development. Neointestinal engineering from intestinal
epithelial organoid units (IEOU) may be a potential alternative
therapy to solve the problems of acute organ shortage and rejection
in short bowel syndrome (SBS) patients. A novel in vitro enzymatic
digestion method to simulate the intestinal stem cell niche was
developed in a rat system. Citrulline, an amino acid exclusively
synthesized by intestinal epithelial cells, was analyzed in a primary
culture for up to 100 days. Three distinct periods of citrulline levels
were observed in the culture system. A strong correlation between
citrulline and lactate was demonstrated. Addition of rodent bone
marrow derived mesenchymal cells increased citrulline synthesis
following long term culture. This cellular niche model and the
inﬂuence of non-hematopoietic cells should have utility in tissue
engineering projects.
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A MOLECULAR PROFILE OF ENDOTHELIAL CELL-DERIVED GROWTH
FACTORS THAT REGULATE STEM CELL SELF-RENEWAL
Himburg, H.1, Muramoto, G.G.1, Salter, A.B.1, Zhai, J.1,
Chi, J.-T.A.1, Chute, J.P.1 1Duke University Medical Center, Durham,
NC.
Several molecular pathways that regulate hematopoietic stem cell
(HSC) self-renewal in the mouse have recently been elucidated,
including Notch, HOXB4, Wnt and bone morphogenetic protein
signaling pathways. However, full elucidation of the intrinsic and
extrinsic mechanisms that regulate human HSC self renewal has
yet to be realized. As a model for identifying extrinsic factors that
stimulate human HSC self-renewal, we have studied the capacity
for vascular endothelial cells to support human HSC expansion ex
vivo. We have found that primary human brain-derived endothelial
cells (HUBECs), unlike all other tissue sources of human ECs we
have studied, support a 1-2 log ampliﬁcation of human bone
marrow and cord blood HSCs in short term culture, in the absence
of contact (Blood 105:576-83, Blood 100:4433-39). These results
indicate that HUBECs are an ideal resource to identify novel
soluble growth factors that trigger human HSC self-renewal and
expansion. In this study, we applied a comprehensive gene expres-
sion strategy to identify the secreted gene products differentially
expressed by HUBECs as compared to ECs from a wide range of
non-brain tissues, including aorta, pulmonary artery, iliac artery,
dermal artery and coronary artery. RNA was isolated from 9
different non-brain ECs and 6 different HUBECs, each of which
has been shown by our laboratory to promote human HSC expan-
sion in vitro. Samples were hybridized to Operon Human v.3
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